Novel markers of squamous differentiation in the urinary bladder
Wenbin Huang(Nanjing Medical University), Liang Cheng(Brown University), Sean R. Williamson(Cleveland Clinic), Robert E. Emerson(Indiana University – Purdue University Indianapolis), Qiu Rao(Indiana University School of Medicine), David J. Grignon(Indiana University School of Medicine), Antonio López-Beltrán(Cordoba University), Muhammad T. Idrees(Indiana University School of Medicine), Rodolfo Montironi(Marche Polytechnic University), John N. Eble(Indiana University – Purdue University Indianapolis), Michael O. Koch(Indiana University School of Medicine), Ming‐Sheng Wang(Xiamen University), Lee Ann Baldridge(Indiana University School of Medicine), Xiao-jun Zhou(Nanjing University), Shaobo Zhang(Indiana University – Purdue University Indianapolis), Noah M. Hahn(Johns Hopkins University)
Cited by 45
Related Papers
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
|Journal of Clinical Oncology|2011|686